Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Policy / Regulatory

In-Depth Analysis of the National Healthcare Security Policy: A Guide to Key Reforms and Implications

Fineline Cube Feb 22, 2025

The National Healthcare Security Administration (NHSA) has unveiled its 2025 priority action list, focusing on...

Policy / Regulatory

State Council’s Draft Plan Boosts Innovative Drug Development via Medical Insurance Reforms

Fineline Cube Feb 22, 2025

The State Council has released a second draft proposal outlining measures to support the high-quality...

Company Medical Device

Roche Unveils Sequencing by Expansion (SBX) Technology for Next-Generation Sequencing

Fineline Cube Feb 22, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the presentation of its proprietary sequencing...

Policy / Regulatory

Shanghai Issues Legal Guidebook for Innovative Drug Marketing

Fineline Cube Feb 22, 2025

The Shanghai Municipal Market Supervision Administration Bureau has delivered a legal guidebook tailored for innovative...

Policy / Regulatory

China Outlines Drug Pricing Reforms, Encourages Insurance Funds for Innovation

Fineline Cube Feb 22, 2025

The Chinese government has released a set of opinions detailing the establishment of a new...

Company Drug

Roche’s Tecentriq Wins Japan Approval for Alveolar Soft Part Sarcoma

Fineline Cube Feb 21, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) and its Japanese partner Chugai Pharmaceutical Co.,...

Company Drug

GSK’s Nucala Receives NMPA Review for COPD Treatment

Fineline Cube Feb 21, 2025

GSK plc (LON: GSK, NYSE: GSK) announced that the National Medical Products Administration (NMPA) has...

Company Drug

Nuwacell Biotech’s NCR101 Approved for ILD Clinical Study by China’s CDE

Fineline Cube Feb 21, 2025

According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has...

Company

Baxter International Reports Q4 2024 Revenues of USD 2.75B, Up 2% YOY

Fineline Cube Feb 21, 2025

Baxter International (NYSE: BAX) announced its fourth-quarter 2024 financial results, reporting revenues of USD 2.75...

Company Deals Medical Device

Horimed Raises USD 13.8M to Advance Optical and Ultrasonic Imaging Tech

Fineline Cube Feb 21, 2025

Horimed, a Tianjin-based medical device firm specializing in optical and ultrasonic medical imaging technology and...

Company Deals

Gene Cradle and Byongen Therapeutics Partner on Next-Generation DMD Gene Therapies

Fineline Cube Feb 21, 2025

Gene Cradle and Byongen Therapeutics, both Beijing-based gene therapy specialists, have formed a strategic alliance...

Company Drug

Bristol-Myers Squibb’s Opdivo Shows Survival Benefit in CheckMate-816 Study

Fineline Cube Feb 21, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) announced the final analysis of overall survival (OS) data from...

Company Drug

Corxel Pharmaceuticals to Test JX10 in Acute Ischemic Stroke Patients with NMPA Approval

Fineline Cube Feb 21, 2025

China-based Corxel Pharmaceuticals (CORXEL) has received approval from the National Medical Products Administration (NMPA) to...

Company Deals

Harbour BioMed and Insilico Medicine Partner on AI-Powered Antibody Development

Fineline Cube Feb 21, 2025

China-based Harbour BioMed (HKG: 2142) announced a strategic partnership with Insilico Medicine, a generative artificial...

Company Drug

Gilead’s Livdelzi Receives Conditional EC Approval for Primary Biliary Cholangitis

Fineline Cube Feb 21, 2025

US-based Gilead Sciences Inc. (NASDAQ: GILD) announced that it has received conditional approval from the...

Company Deals

FibroGen to Sell China Subsidiary to AstraZeneca for ~$160M, Roxadustat Rights Included

Fineline Cube Feb 21, 2025

US-based biopharma FibroGen Inc. (NASDAQ: FGEN) has entered into an agreement to sell its China...

Company Deals

Waterdrop Integrates DeepSeek AI to Boost Insurance Ecosystem

Fineline Cube Feb 21, 2025

China-based Waterdrop Inc. (NYSE: WDH), a crowdfunding-based health insurance platform, announced a strategic integration with...

Company Drug

Boehringer Ingelheim Launches LENTICLAIR Study for CF Gene Therapy BI 3720931

Fineline Cube Feb 21, 2025

German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for...

Company Drug

Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review

Fineline Cube Feb 21, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...

Policy / Regulatory

Stabilizing Foreign Investment: China’s Comprehensive Action Plan for 2025

Fineline Cube Feb 20, 2025

In a significant move to bolster foreign investment and enhance the country’s economic openness, the...

Posts pagination

1 … 248 249 250 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.